Drug Profile
Research programme: cancer therapeutics - Bristol-Myers Squibb/The Institute for Research in Immunology and Cancer
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; University of Montreal
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer